John W. Babich

Ratio Therapeutics, Inc. is a pharmaceutical company based in the United States. The company is based in Boston, MA. The company's mission is to accelerate the development of next-generation precision radiopharmaceuticals for solid tumors and transform oncology treatment paradigms. The company's fully integrated proprietary R&D platforms, Trillium™ and Macropa™, enable the imaging, discovery, and advancement of novel radiopharmaceuticals that have first/best-in-class delivery, safety, and efficacy properties. Founded by John Babich, Ph.D., and Jack Hoppin, Ph.D., the company employs a growing team of radiopharmaceuticals discovery and development experts with backgrounds in the life science industry. The CEO of the company is Jack William Hoppin.

Ratio Therapeutics, Inc. is a pharmaceutical company based in the United States. The company is based in Boston, MA. The company's mission is to accelerate the development of next-generation precision radiopharmaceuticals for solid tumors and transform oncology treatment paradigms. The company's fully integrated proprietary R&D platforms, Trillium™ and Macropa™, enable the imaging, discovery, and advancement of novel radiopharmaceuticals that have first/best-in-class delivery, safety, and efficacy properties. Founded by John Babich, Ph.D., and Jack Hoppin, Ph.D., the company employs a growing team of radiopharmaceuticals discovery and development experts with backgrounds in the life science industry. The CEO of the company is Jack William Hoppin.

Ratio Therapeutics, Inc. is a pharmaceutical company based in the United States. The company is based in Boston, MA. The company's mission is to accelerate the development of next-generation precision radiopharmaceuticals for solid tumors and transform oncology treatment paradigms. The company's fully integrated proprietary R&D platforms, Trillium™ and Macropa™, enable the imaging, discovery, and advancement of novel radiopharmaceuticals that have first/best-in-class delivery, safety, and efficacy properties. Founded by John Babich, Ph.D., and Jack Hoppin, Ph.D., the company employs a growing team of radiopharmaceuticals discovery and development experts with backgrounds in the life science industry. The CEO of the company is Jack William Hoppin.